Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab in Chronic HIV Infection (HAVARTI)
NCT03147859Phase 2Unknown
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Nov 2017
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of vedolizumab in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Vedolizumab safety and tolerance at 12 months. Status: unknown.
02
Drugs
vedolizumab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03147859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03147859.